39 results about "Immunomodulatory peptide" patented technology

The invention provides a culture method for improving immunity of fishes. The culture method comprises the following steps: S1, selection of culture points; S2, specification and layout of net cages; S3, selection and throwing of fish fries; according to the fry disinfection method disclosed by the invention, the fry are soaked and disinfected by using a compound disinfectant prepared from povidone iodine, polysorbate, citric acid and vitamin C in a specific proportion, so that pathogenic microorganisms on the surfaces and gill parts of fish bodies are effectively killed. According to the breeding management, the immunity of the fish body is comprehensively enhanced by feeding the fish with an immune conditioner composed of campesterol palmitate, immunomodulatory peptide, beta-glucan and astaxanthin in a specific proportion. According to the bottom mud management, the content of harmful substances is reduced by putting a bottom mud modifier composed of sodium molybdate, nitrifying bacteria, photosynthetic bacteria, tetrandrine and sodium alginate in a specific proportion, growth of pathogenic bacteria is inhibited, nutrient substance circulation is promoted, the water quality environment is optimized, and healthy growth of fry is promoted.

The invention relates to the technical field of preparation methods of giant salamander peptide and eucommia ulmoides male flower tablets, in particular to a preparation method of giant salamander peptide and eucommia ulmoides male flower tablets. The giant salamander peptide and eucommia ulmoides male flower tablets comprise the following raw materials in parts by weight: 30-40 parts of giant salamander peptide powder, 20-25 parts of eucommia ulmoides male flowers, 10-15 parts of rape pollen, 10-15 parts of sea cucumber intestine peptide powder, 10-12 parts of a filler, 3-5 parts of an adhesive and 1-3 parts of a lubricant. According to the invention, the eucommia male flower contains geniposidic acid, chlorogenic acid, aucubin lignin, iridoid and phenylpropanoid natural active nutrient substances, flavonoid compounds, polysaccharide and other bioactive substances in the rape pollen, polysaccharide and peptide components in the sea cucumber intestine peptide powder, and the like. The andrias davidianus peptide powder is added into the andrias davidianus peptide powder, the andrias davidianus peptide powder cooperates with antioxidant peptide and immunomodulatory peptide in the andrias davidianus peptide powder to jointly form a rich bioactive substance library, and the components regulate the physiological functions of the human body from different angles, provide comprehensive nutrition support for the body and improve the fatigue resistance of the human body.

The invention belongs to the technical field of food biology, and discloses an abalone-derived immunomodulatory peptide as well as a preparation method and application thereof. The abalone source immunomodulatory peptide is obtained by combining double-enzyme enzymolysis and molecular docking screening, and comprises at least one of peptides with amino acid sequences shown as SEQ.ID.NO.1-6, and the docking energy of the peptides and a receptor TLR4 is-7.4 kcal / mol,-6.9 kcal / mol,-6.8 kcal / mol,-6.8 kcal / mol,-6.8 kcal / mol and-6.6 kcal / mol in sequence respectively. Experiments prove that the abalone peptide has high immunocompetence, can provide a basis for application of the abalone-derived immunomodulatory peptide in preparation of functional food from natural food sources, and has important significance for development of novel immunomodulatory peptide products.

The invention discloses a preparation method and application of a milk-derived immunomodulatory peptide, milk-derived casein is taken as a raw material, known immunomodulatory peptide is screened, virtual enzymolysis is performed on the known immunomodulatory peptide, and the immunomodulatory peptide is separated and prepared by a verification and freeze drying method. The casein can be subjected to targeted enzymolysis, the relative content and variety of the immunomodulatory peptide are increased, the situation that the immunomodulatory effect of other immunomodulatory casein peptide products is measured after pure enzymolysis, and the efficacy of the immunomodulatory peptide is not enhanced is reduced, the better immunomodulatory effect is achieved, and the immune cell proliferation effect is effectively promoted.

The invention provides an allosteric nanogel adjuvant as well as a preparation method and application thereof, and belongs to the technical field of vaccines. The allosteric nanogel adjuvant comprises a self-assembly motif, a responsive site and an immunomodulatory peptide fragment, and the self-assembly motif is composed of 2-5 amino acids; the allosteric nanogel adjuvant has a structure as shown in a formula I, and is named as NTP5 for short; the allosteric nanogel adjuvant is self-assembled into nanoparticles, the nanoparticles are allosteric into a nanofiber structure through responsive broken bonds, nanogel is further formed, and the key problems of a traditional vaccine in the aspects of antigen delivery and immune activation are effectively solved. The nanogel adjuvant can efficiently load various antigens to form a stable nano vaccine, activate an immune microenvironment and provide more means and thoughts for vaccine development.

The invention discloses a ternary fusion polypeptide Col-TF-1 targeting senescence cells, a monoclonal antibody mAb SC-1 matched with the ternary fusion polypeptide Col-TF-1, an anti-aging composition containing the ternary fusion polypeptide Col-TF-1 and the monoclonal antibody mAb SC-1, and application of the ternary fusion polypeptide Col-TF-1 The fusion polypeptide is formed by connecting a targeting peptide for targeting a senescence cell surface uPAR receptor, a collagen active peptide for promoting collagen synthesis and an immunomodulatory peptide for activating NK cells in series through a flexible linker GGGGS, and the amino acid sequence is as shown in SEQ ID NO.1. The invention further discloses a preparation method of the fusion polypeptide. Through CDR region humanized reconstruction and pH sensitive histidine switch design, the affinity of the matched antibody mAb SC-1 is improved by 5 times in a subacid environment, and the ADCC effect is enhanced through fucose-deficient host cells. Experiments show that when the fusion polypeptide is combined with the antibody, the senescent cell clearance rate can reach 45.2%, the collagen density is increased by 83.5%, and the effect is obviously superior to that of a single drug. The composition provided by the invention can be applied to the fields of cosmetics, medical instruments, medicines and functional foods, and provides a new strategy for treatment of senescence-related diseases and development of anti-senescence products.

The present invention relates to a novel immunoregulatory peptide having the ability to control inflammatory responses, and a use thereof. The peptide of the present invention may be useful in the treatment of inflammation, various immune diseases, or cancer, by regulating the activity of immune cells.

The application relates to the field of biotechnology, and particularly discloses an immunoregulatory peptide as well as a preparation method and application thereof. Three new polypeptides with ideal immunoregulatory effects are found through specific enzymolysis and screening, and the polypeptides have the amino acid sequences shown in any one or more of SEQ ID No. 1-3. The application enriches the types of milk-derived bioactive peptides, and provides new raw materials for preparing immunoregulatory effect products.

The application discloses an immunoregulatory peptide BugaCATH and application thereof, and belongs to the field of biomedicine. Buga The CATH is a cyclic polypeptide with a pair of intramolecular disulfide bond composed of a sixth cysteine and a thirteenth cysteine, and has a molecular weight of 3156.67 Dalton and an isoelectric point of 8.76, wherein the amino acid sequence is shown as SEQ ID NO: 2. Buga The gene (GenBank accession: OQ870533) of the CATH precursor is composed of 663 nucleotide sequences, and the nucleotide sequence is shown as SEQ ID NO: 1; wherein the nucleotide at the positions of 322-448 is the immunoregulatory peptide Buga The encoding gene of the CATH. The immunoregulatory peptide Buga The application of the CATH in the preparation of a treatment drug for promoting skin wound repair.

The invention belongs to the fields of traditional Chinese medicines and proteins, provides application of Xiaochaihu decoction in preparation of a medicine for treating peritoneal dialysis related peritonitis, and identifies various antibacterial and immunomodulatory peptides from the Xiaochaihu decoction. The application proves that the common goldenrop decoction has a remarkable adjuvant therapy effect on peritoneal dialysis related peritonitis, and the antibacterial and immunomodulatory polypeptide identified on the basis has remarkable antibacterial and immunomodulatory activity, so that a good basis is provided for further development of medicines.

The present invention provides a breeding method for improving fish immunity, comprising the following steps: S1. breeding site selection, S2. cage specifications and layout, S3. fry selection and placement, S4. fry disinfection, S5. adaptability training S6. breeding management, S7. bottom mud management. The fry disinfection of the present invention is carried out by soaking and disinfecting the fry with a composite disinfectant composed of povidone iodine, polysorbate, citric acid, and vitamin C in a specific proportion, effectively killing pathogenic microorganisms on the surface of the fish and the gills. The breeding management of the present invention comprehensively enhances the immunity of the fish by feeding an immunomodulator composed of a specific proportion of rape sterol palmitate, immunomodulatory peptide, β-glucan, and astaxanthin. The bottom mud management of the present invention reduces the content of harmful substances, inhibits the growth of pathogenic bacteria, promotes the circulation of nutrients and optimizes the water quality environment by placing a bottom mud modifier composed of a specific proportion of sodium molybdate, nitrifying bacteria, photosynthetic bacteria, tetrandrine, and sodium alginate, and promotes the healthy growth of fry.

The present invention belongs to the technical field of bioactive peptides, and discloses immunomodulatory nonapeptides and applications. The immunomodulatory peptide provided by the present invention is extracted from white mullet, and the amino acid sequence is shown in SEQ ID NO.1. It is safe and has no toxic side effects, can significantly enhance the phagocytic ability of RAW264.7 cells, and has a strong immunomodulatory function.

The application provides an Euphausia superba immunomodulatory peptide, which is prepared by alkaline protease and flavour protease for enzymolysis, and then the enzymolysis product is purified by cation exchange chromatography, Sephadex G25 gel chromatography and C18 reverse phase high performance liquid chromatography. The amino acid sequence of a polypeptide is SEQ ID NO: 1 or SEQ ID NO: 2. The Euphausia superba is used as raw material, Euphausia superba peptides are obtained by enzymolysis, and the amino acid sequences of the Euphausia superba peptides are analyzed and identified by LC-MS / MS after step-by-step purification. With the help of an activity prediction tool and molecular docking, a target peptide with good immunomodulatory activity potential is screened. The target peptide is artificially synthesized, the immunomodulatory activity is verified, and the action mechanism is further clarified. Data support is provided for the prediction screening and structure-activity relationship research of Euphausia superba source high-efficiency immunomodulatory peptides.

This invention belongs to the field of food biotechnology and discloses an abalone-derived immunomodulatory peptide, its preparation method, and its application. The abalone-derived immunomodulatory peptide of this invention is obtained through a combination of dual-enzyme digestion and molecular docking screening. It includes at least one peptide with amino acid sequences as shown in SEQ ID NO. 1-6, and the docking energies with the receptor TLR4 are -7.4 kcal / mol, -6.9 kcal / mol, -6.8 kcal / mol, -6.8 kcal / mol, -6.8 kcal / mol, and -6.6 kcal / mol, respectively. Experiments have demonstrated that the above-mentioned abalone peptide possesses high immunomodulatory activity, providing a foundation for its application in the preparation of functional foods from natural food sources, and is of great significance for the development of novel immunomodulatory peptide products.

This invention specifically relates to spirulina immunomodulatory peptides, their preparation methods, and applications, belonging to the field of protein bioactive peptide technology. This invention is the first to screen immunomodulatory peptides Ser-Pro-Ser-Trp-Tyr (SPSWY), Met-Phe-Asp-Ala-Phe (MFDAF), and Phe-Gly-Arg-Phe-Arg (FGRFR) from spirulina phycocyanin. The structure and immunomodulatory activity of peptides SPSWY, MFDAF, and FGRFR were clarified. Peptides SPSWY, MFDAF, and FGRFR can enhance macrophage cell viability and phagocytic capacity, and also increase the secretion of NO and cytokines by macrophages. Their immunomodulatory activity also exhibits good stability. Furthermore, peptides SPSWY, MFDAF, and FGRFR have the advantages of being safe, non-toxic, and having high biological activity.

The present disclosure provides variant immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.

The present disclosure provides variant immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.

The present invention relates to a novel immunoregulatory peptide having an inflammatory response control function and its use. The peptide of the present invention can be usefully used in the treatment of inflammation, various immune diseases, and cancer by regulating the activity of immune cells.

This invention relates to the field of biomedical technology, and particularly to a process for preparing chicken thymus immunomodulatory peptides using a compound enzymatic hydrolysis method, the chicken thymus immunomodulatory peptides, and their applications. The steps are as follows: First, the chicken thymus tissue is pretreated, including thawing, cutting, microwave-assisted treatment, and high-speed homogenization. Then, pepsin pre-hydrolysis is performed, the pH is adjusted, and pepsin is added to the reaction. Next, the hydrolysis is optimized by pH gradient conversion (pH 4.8-5.2→6.3-6.7→7.3-7.7), followed by trypsin secondary hydrolysis. Then, the peptides are purified using a gradient membrane separation system (10kDa, 1kDa, 500Da), and the 1kDa-500Da fraction is collected. Finally, the collected fraction is concentrated and freeze-dried to obtain the target peptide. This process combines enzymatic hydrolysis and membrane separation technology to effectively extract highly active immunomodulatory peptides. The yield of active peptides in this invention is increased by approximately 42%, and the purity is increased by approximately 28%.

This invention belongs to the field of biotechnology, specifically relating to a highly immunomodulatory peptide derived from silkworm pupa protein, its preparation method, and its applications. The invention provides a silkworm pupa protein immunomodulatory peptide, the amino acid sequence of which is shown in SEQ ID NO.2, SEQ ID NO.3, and / or SEQ ID NO.8. This silkworm pupa protein immunomodulatory peptide is prepared by hydrolyzing silkworm pupa protein with alkaline protease, followed by purification of the enzymatic hydrolysis product through ultrafiltration and gel filtration. The most immunomodulatory peptide is screened by determining the immunomodulatory activity index, and identified by LC-MS / MS to obtain a highly immunomodulatory peptide derived from silkworm pupa protein. This immunomodulatory peptide strongly binds to TLR2 and TLR4 / MD-2 receptors through hydrogen bonds and hydrophobic interactions, activating immunity and effectively promoting macrophage proliferation and phagocytosis. This immunomodulatory peptide exhibits good immunomodulatory activity and can be used as a potential functional food ingredient.

The subject invention relates to a novel bead-based platform that can be used to screen various immunologically active peptides with immunogenic or tolerogenic potential and to design peptide candidates and combinations thereof. More specifically, the subject invention uses peptides specified in parametric fashion to increase their efficiency of differentiation of immune cells.

The present invention relates to an isolated peptide consisting of a sequence of 3 to 39 amino acids derived from the amino acid sequence SEQ ID NO: 1, said peptide having a sequence of amino acids selected from the group consisting of:a) sequences of 3 to 39 amino acids comprising at least the residues 6 to 8 of SEQ ID NO: 1, andb) sequences of 3 to 39 amino acids having at least 70% identity with said sequence in a).

The invention relates to an immunomodulatory peptide Puerein and application thereof, and belongs to the field of biomedicine. The immunomodulatory peptide Puerein is a polypeptide coded by a defensive peptide gene of a special species Pu'er pan tree frog in China, the molecular weight is 1486.7 Dalton, the isoelectric point is 12.58, and the amino acid sequence of the immunomodulatory peptide Puerein is as shown in SEQ ID NO: 2. The gene GenBank access No.PQ862905 for coding the precursor of the immunomodulatory peptide Puerein is composed of 592 nucleotide sequences, and the nucleotide sequence of the gene GenBank access No.PQ862905 is as shown in SEQ ID NO: 1; wherein the 399th to 435th nucleotides are coding genes of the mature Pu'er ubiquitous frog multifunctional immunomodulatory peptide Puerein. The invention further discloses application of the Pu'er pan-tree frog immunomodulatory peptide Puerein in preparation of anti-oxidation, damaged DNA (deoxyribonucleic acid) removal and skin light damage resistance. The composition has the beneficial effects that the composition has a relatively strong skin light injury resisting effect on the skin and can remarkably inhibit the occurrence of skin light injury.

The application discloses an immunomodulatory peptide Ha-CATH and application thereof, and belongs to the field of biomedicine. The immunomodulatory peptide Ha-CATH is a cyclic polypeptide with a pair of intramolecular disulfide bonds formed by the eighth cysteine residue and the thirteenth cysteine residue of a skin repair peptide gene of Chinese amphibian Pelophylax nigromaculatus, has a molecular weight of 2361.8 Dalton, an isoelectric point of 6.04, and an amino acid sequence shown in SEQ ID NO:1. A gene (GenBank accession: OQ992774) encoding the precursor of the immunomodulatory peptide Ha-CATH is composed of 714 nucleotides, has a nucleotide sequence shown in SEQ ID NO:2, and the nucleotide sequence of 445-504 is the encoding gene of the immunomodulatory peptide Ha-CATH. ‑ The application also discloses an application of the immunomodulatory peptide Ha-CATH in preparation of a skin wound repair promoting therapeutic drug. ‑ The application also discloses an application of the immunomodulatory peptide Ha-CATH in preparation of a skin wound repair promoting therapeutic drug.

The present disclosure provides T-cell modulatory multimeric polypeptides (T-Cell-MMP) and their epitope conjugates comprising at least one immunomodulatory polypeptide (“MOD”) that may be selected to exhibit reduced binding affinity to a cognate co-immunomodulatory polypeptide (“Co-MOD”). The epitope may be, for example, a cancer-associated epitope, an infectious disease-associated epitope, or a self-epitope. The T-Cell-MMP-epitope conjugates are useful for modulating the activity of a T-cell by delivering immunomodulatory peptides, such as IL-2 or IL-2 variants that exhibit reduced binding affinity for the IL-2R, to T-cells in an epitope selective / specific manner, and accordingly, for treating individuals with a cancer, infectious disease or autoimmune disorder.

The invention relates to the technical field of biological pharmacy, and discloses an MPL composite adjuvant which comprises the following components in parts by mass: 10-20 parts of MPL; 5 to 15 parts by mass of immunomodulatory peptide; the mass part of the nano carrier is 20 to 40 parts; 1-5 parts by mass of an auxiliary stable component; the preparation method of the MPL composite adjuvant comprises the following steps: dissolving MPL in an organic solvent to obtain an MPL solution, dissolving immunomodulatory peptide in a buffer solution, adding a nano-carrier solution into the mixed solution, filtering the mixed solution, and converting the mixed solution into a solid form through freeze drying, the MPL composite adjuvant is applied to vaccine development. According to the invention, a nano-carrier technology of combining lecithin and vitamin E is adopted, so that the stability and immune activation capability of the MPL composite adjuvant are improved, and the immune effect is improved.

Aspects of the present disclosure include methods for modulating macrophage activity. Methods according to certain embodiments include contacting a macrophage with a mannose receptor (CD206) binding agent in a manner sufficient to modulate activity of the macrophage. Methods for converting a phenotype of a macrophage from an M2 phenotype to an M1 phenotype are also provided. Methods for inhibiting growth of a CD206-expressing cell as well as methods for treating a subject for a neoplastic condition (e.g., cancer) or a condition associated with chronic inflammation are described. Immuno-modulating peptides suitable for use in the subject methods are also presented.

The application discloses frog meat protein source active peptides and application thereof in preparation of immunomodulators, and belongs to the technical field of active peptides. Two novel immunomodulatory peptides GIHETTYNS and IVRDIKEK are identified from the hydrolysate of Rana spinosa meat, which can significantly improve the proliferation activity of macrophage RAW264.7, accelerate the cell cycle, promote the production of NO and cytokines, and improve the level of active oxygen. The results of inflammation reaction experiments show that the active peptides can relieve inflammation. The results of molecular docking show that the active peptides are combined with the key region of TLR4 / MD-2 through hydrogen bond and hydrophobic interaction. In addition, bioinformatics analysis shows that the active peptides have good safety and stability. In summary, the active peptides are expected to become new raw materials of natural immunomodulators and anti-inflammatory agents, and promote the high-value utilization of Rana spinosa.

The application discloses a preparation method of lactoferrin immunomodulatory peptide and application thereof. The application provides recombinant escherichia coli which is escherichia coli capable of expressing fusion protein SUMO-LF(IMP); the fusion protein SUMO-LF(IMP) is fused by a SUMO tag and lactoferrin immunomodulatory peptide (SEQ ID NO:1 or SEQ ID NO:2 or SEQ ID NO:3). The recombinant strain of the application can efficiently express target protein, the expressed immunomodulatory active fragment retains natural immunomodulatory activity, and the prokaryotic expression system has the advantages of low culture cost, short fermentation period, easy separation and purification of protein and the like, the constructed strain can produce immunomodulatory active fragments on a large scale, provides a core production strain for product development in the fields of immunomodulators, biological pharmaceuticals, functional food additives and the like, and has important industrial application value and market prospect.

The invention develops a method for rapidly screening bovine colostrum immunomodulatory peptides based on DPPH free radical scavenging rate. The optimal enzymolysis conditions (alkaline protease, 5.01%, 2355.46 U / g and 4.59 h) are determined through multi-enzyme system screening and response surface optimization, and the feasibility of rapid screening based on the DPPH free radical scavenging rate is verified through correlation analysis of the DPPH free radical scavenging rate and macrophage phagocytic activity. The active peptide smaller than 3kDa is obtained through ultrafiltration and LC-MS / MS identification, the immunoregulation effect of the active peptide is remarkable, the screening efficiency is greatly improved compared with that of a traditional method, and an efficient and reliable technical scheme is provided for large-scale preparation of the food-borne immunoregulation peptide.